{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:10:21Z","timestamp":1792098621105,"version":"4.4.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T00:00:00Z","timestamp":1627689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T00:00:00Z","timestamp":1627689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Cardiovasc Imaging"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s10554-021-02363-4","type":"journal-article","created":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T09:02:53Z","timestamp":1627722173000},"page":"195-209","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Safety and tolerability of regadenoson in comparison with adenosine stress cardiovascular magnetic resonance: Data from a multicentre prospective registry"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1271-0520","authenticated-orcid":false,"given":"Jose V.","family":"Monmeneu Menadas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria P.","family":"Garc\u00eda Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria P.","family":"Lopez-Lereu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Higueras Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia M.","family":"Maceira Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,31]]},"reference":[{"issue":"3","key":"2363_CR1","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","volume":"41","author":"J Knuuti","year":"2020","unstructured":"Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C et al (2020) 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 41(3):407\u2013477. https:\/\/doi.org\/10.1093\/eurheartj\/ehz425 (PMID: 31504439)","journal-title":"Eur Heart J"},{"issue":"9814","key":"2363_CR2","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S0140-6736(11)61335-4","volume":"379","author":"JP Greenwood","year":"2012","unstructured":"Greenwood JP, Maredia N, Younger JF, Brown JM, Nixon J, Everett CC et al (2012) Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial. Lancet 379(9814):453\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(11)61335-4","journal-title":"Lancet"},{"key":"2363_CR3","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1093\/eurheartj\/ehy267","volume":"39","author":"J Knuuti","year":"2018","unstructured":"Knuuti J, Ballo H, Juarez-Orozco LE, Saraste A, Kolh P, Saskia Rutjes AW et al (2018) The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-analysis focused on post-test disease probability. Eur Heart J 39:3322\u20133330. https:\/\/doi.org\/10.1093\/eurheartj\/ehy267","journal-title":"Eur Heart J"},{"issue":"13","key":"2363_CR4","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1161\/CIRCULATIONAHA.106.652016","volume":"115","author":"C Jahnke","year":"2007","unstructured":"Jahnke C, Nagel E, Gebker R, Kokocinski T, Kelle S, Manka R et al (2007) Prognostic value of cardiac magnetic resonance stress tests: adenosine stress perfusion and dobutamine stress wall motion imaging. Circulation 115(13):1769\u20131776. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.652016","journal-title":"Circulation"},{"issue":"1","key":"2363_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1148\/radiol.11110134","volume":"262","author":"V Bodi","year":"2012","unstructured":"Bodi V, Husser O, Sanchis J, N\u00fa\u00f1ez J, Monmeneu JV, L\u00f3pez-Lereu MP et al (2012) Prognostic implications of dipyridamole cardiac MR imaging: a prospective multicenter registry. Radiology 262(1):91\u2013100. https:\/\/doi.org\/10.1148\/radiol.11110134","journal-title":"Radiology"},{"issue":"25","key":"2363_CR6","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1056\/NEJMoa1716734","volume":"380","author":"E Nagel","year":"2019","unstructured":"Nagel E, Greenwood JP, McCann GP, Bettencourt N, Shah AM, Hussain ST et al (2019) Magnetic resonance perfusion or fractional flow reserve in coronary disease. N Engl J Med 380(25):2418\u20132428. https:\/\/doi.org\/10.1056\/NEJMoa1716734","journal-title":"N Engl J Med"},{"issue":"13","key":"2363_CR7","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.jacc.2009.04.089","volume":"54","author":"W Al Jaroudi","year":"2009","unstructured":"Al Jaroudi W, Iskandrian AE (2009) Regadenoson: a new myocardial stress agent. J Am Coll Cardiol 54(13):1123\u20131130. https:\/\/doi.org\/10.1016\/j.jacc.2009.04.089","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2363_CR8","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1007\/s12350-015-0387-x","volume":"23","author":"MJ Henzlova","year":"2016","unstructured":"Henzlova MJ, Duvall WL, Einstein AJ, Travin MI, Verberne HJ (2016) ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers. J Nucl Cardiol 23(3):606\u2013639. https:\/\/doi.org\/10.1007\/s12350-015-0387-x","journal-title":"J Nucl Cardiol"},{"issue":"3","key":"2363_CR9","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3109\/14017431.2016.1163415","volume":"50","author":"M Pape","year":"2016","unstructured":"Pape M, Zacho HD, Aar\u00f8e J, Eggert Jensen S, Petersen LJ (2016) Safety and tolerability of regadenoson for myocardial perfusion imaging\u2014first Danish experience. Scand Cardiovasc J 50(3):180\u2013186. https:\/\/doi.org\/10.3109\/14017431.2016.1163415","journal-title":"Scand Cardiovasc J"},{"issue":"11","key":"2363_CR10","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1016\/j.jacc.2005.05.097","volume":"46","author":"RC Hendel","year":"2005","unstructured":"Hendel RC, Bateman TM, Cerqueira MD, Iskandrian AE, Leppo JA, Blackburn B et al (2005) Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging. J Am Coll Cardiol 46(11):2069\u20132075. https:\/\/doi.org\/10.1016\/j.jacc.2005.05.097","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2363_CR11","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.nuclcard.2007.06.114","volume":"14","author":"AE Iskandrian","year":"2007","unstructured":"Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC et al (2007) Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol. 14(5):645\u201358. https:\/\/doi.org\/10.1016\/j.nuclcard.2007.06.114","journal-title":"J Nucl Cardiol."},{"issue":"3","key":"2363_CR12","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jcmg.2008.02.003","volume":"1","author":"MD Cerqueira","year":"2008","unstructured":"Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE (2008) Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results. JACC Cardiovasc Imaging 1(3):307\u2013316. https:\/\/doi.org\/10.1016\/j.jcmg.2008.02.003","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"2363_CR13","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1148\/radiol.12112475","volume":"265","author":"G Tarroni","year":"2012","unstructured":"Tarroni G, Corsi C, Antkowiak PF, Veronesi F, Kramer CM, Epstein FH et al (2012) Myocardial perfusion: near-automated evaluation from contrast-enhanced MR images obtained at rest and during vasodilator stress. Radiology 265(2):576\u201383. https:\/\/doi.org\/10.1148\/radiol.12112475","journal-title":"Radiology"},{"issue":"6","key":"2363_CR14","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s10554-011-9949-4","volume":"28","author":"EV DiBella","year":"2012","unstructured":"DiBella EV, Fluckiger JU, Chen L, Kim TH, Pack NA, Matthews B et al (2012) The effect of obesity on regadenoson-induced myocardial hyperemia: a quantitative magnetic resonance imaging study. Int J Cardiovasc Imaging. 28(6):1435\u201344. https:\/\/doi.org\/10.1007\/s10554-011-9949-4","journal-title":"Int J Cardiovasc Imaging."},{"issue":"7","key":"2363_CR15","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1093\/ehjci\/jet278","volume":"15","author":"KL Nguyen","year":"2014","unstructured":"Nguyen KL, Bandettini WP, Shanbhag S, Leung SW, Wilson JR, Arai AE (2014) Safety and tolerability of regadenoson CMR. Eur Heart J Cardiovasc Imaging 15(7):753\u201360. https:\/\/doi.org\/10.1093\/ehjci\/jet278","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"1","key":"2363_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1532-429X-15-91","volume":"15","author":"CM Kramer","year":"2013","unstructured":"Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E (2013) Society for cardiovascular magnetic resonance board of trustees task force on standardized protocols. Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update. J Cardiovasc Magn Reson 15(1):91. https:\/\/doi.org\/10.1186\/1532-429X-15-91","journal-title":"J Cardiovasc Magn Reson"},{"issue":"1","key":"2363_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1148\/radiol.2401051161","volume":"240","author":"RC Cury","year":"2006","unstructured":"Cury RC, Cattani CA, Gabure LA, Racy DJ, de Gois JM, Siebert U et al (2006) Diagnostic performance of stress perfusion and delayed-enhancement MR imaging in patients with coronary artery disease. Radiology 240(1):39\u201345. https:\/\/doi.org\/10.1148\/radiol.2401051161","journal-title":"Radiology"},{"issue":"14","key":"2363_CR18","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.ehj.2003.11.018","volume":"25","author":"A Wahl","year":"2004","unstructured":"Wahl A, Paetsch I, Gollesch A, Roethemeyer S, Foell D, Gebker R et al (2004) Safety and feasibility of high-dose dobutamine-atropine stress cardiovascular magnetic resonance for diagnosis of myocardial ischaemia: experience in 1000 consecutive cases. Eur Heart J 25(14):1230\u20131236. https:\/\/doi.org\/10.1016\/j.ehj.2003.11.018","journal-title":"Eur Heart J"},{"issue":"1","key":"2363_CR19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1093\/ehjci\/jes125","volume":"14","author":"F von Knobelsdorff-Brenkenhoff","year":"2013","unstructured":"von Knobelsdorff-Brenkenhoff F, Bublak A, El-Mahmoud S, Wassmuth R, Opitz C, Schulz-Menger J (2013) Single-centre survey of the application of cardiovascular magnetic resonance in clinical routine. Eur Heart J Cardiovasc Imaging 14(1):62\u201368. https:\/\/doi.org\/10.1093\/ehjci\/jes125","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"3","key":"2363_CR20","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/ehjci\/jev153","volume":"17","author":"JV Monmeneu Menadas","year":"2016","unstructured":"Monmeneu Menadas JV, Lopez-Lereu MP, Estornell Erill J, Garcia Gonzalez P, Igual Mu\u00f1oz B, Maceira GA (2016) Pharmacological stress cardiovascular magnetic resonance: feasibility and safety in a large multicentre prospective registry. Eur Heart J Cardiovasc Imaging 17(3):308\u2013315. https:\/\/doi.org\/10.1093\/ehjci\/jev153","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"9","key":"2363_CR21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2147\/COPD.S56879","volume":"22","author":"Y Golzar","year":"2014","unstructured":"Golzar Y, Doukky R (2014) Regadenoson use in patients with chronic obstructive pulmonary disease: the state of current knowledge. Int J Chron Obstruct Pulmon Dis 22(9):129\u2013137. https:\/\/doi.org\/10.2147\/COPD.S56879","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"15","key":"2363_CR22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1532-429X-15-85","volume":"24","author":"S Vasu","year":"2013","unstructured":"Vasu S, Bandettini WP, Hsu LY, Kellman P, Leung S, Mancini C et al (2013) Regadenoson and adenosine are equivalent vasodilators and are superior than dipyridamole\u2014a study of first pass quantitative perfusion cardiovascular magnetic resonance. J Cardiovasc Magn Reson 24(15):85. https:\/\/doi.org\/10.1186\/1532-429X-15-85","journal-title":"J Cardiovasc Magn Reson"},{"issue":"10","key":"2363_CR23","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1002\/clc.23052","volume":"41","author":"JA Edward","year":"2018","unstructured":"Edward JA, Lee JH, White CJ, Morin DP, Bober R (2018) Intravenous regadenoson with aminophylline reversal is safe and equivalent to intravenous adenosine infusion for fractional flow reserve measurements. Clin Cardiol 41(10):1348\u20131352. https:\/\/doi.org\/10.1002\/clc.23052","journal-title":"Clin Cardiol"},{"issue":"2","key":"2363_CR24","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.carrev.2017.07.004","volume":"19","author":"JZ Lee","year":"2018","unstructured":"Lee JZ, Singh N, Nyotowidjojo I, Howe C, Low SW, Nguyen T et al (2018) Comparison of regadenoson and nitroprusside to adenosine for measurement of fractional flow reserve: a systematic review and meta-analysis. Cardiovasc Revasc Med 19(2):168\u2013174. https:\/\/doi.org\/10.1016\/j.carrev.2017.07.004","journal-title":"Cardiovasc Revasc Med"},{"issue":"2","key":"2363_CR25","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1124\/jpet.105.095323","volume":"316","author":"AK Dhalla","year":"2006","unstructured":"Dhalla AK, Wong MY, Wang WQ, Biaggioni I, Belardinelli L (2006) Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats. J Pharmacol Exp Ther 316(2):695\u2013702. https:\/\/doi.org\/10.1124\/jpet.105.095323","journal-title":"J Pharmacol Exp Ther"},{"issue":"7 Pt 1","key":"2363_CR26","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.jcmg.2019.01.017","volume":"12","author":"LA Derbas","year":"2019","unstructured":"Derbas LA, Thomas GS, Medina CA, Abdel-Karim AA, Saeed IM, Bateman TM (2019) Severe bradycardia and asystole following regadenoson in pharmacological myocardial perfusion imaging: cases and treatment recommendations. JACC Cardiovasc Imaging 12(7 Pt 1):1288\u20131290. https:\/\/doi.org\/10.1016\/j.jcmg.2019.01.017","journal-title":"JACC Cardiovasc Imaging"},{"issue":"15","key":"2363_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1532-429X-15-9","volume":"18","author":"O Bruder","year":"2013","unstructured":"Bruder O, Wagner A, Lombardi M, Schwitter J, van Rossum A, Pilz G et al (2013) European cardiovascular magnetic resonance (EuroCMR) registry\u2013multi national results from 57 centers in 15 countries. J Cardiovasc Magn Reson 18(15):9. https:\/\/doi.org\/10.1186\/1532-429X-15-9","journal-title":"J Cardiovasc Magn Reson"},{"issue":"10","key":"2363_CR28","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1007\/s00330-004-2425-y","volume":"14","author":"D Kuijpers","year":"2004","unstructured":"Kuijpers D, Janssen CH, van Dijkman PR, Oudkerk M (2004) Dobutamine stress MRI. Part I. Safety and feasibility of dobutamine cardiovascular magnetic resonance in patients suspected of myocardial ischemia. Eur Radiol 14(10):1823\u20131828. https:\/\/doi.org\/10.1007\/s00330-004-2425-y","journal-title":"Eur Radiol"},{"issue":"4","key":"2363_CR29","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1007\/s12350-016-0427-1","volume":"24","author":"N Hussain","year":"2017","unstructured":"Hussain N, Chaudhry W, Ahlberg AW, Amara RS, Elfar A, Parker MW et al (2017) An assessment of the safety, hemodynamic response, and diagnostic accuracy of commonly used vasodilator stressors in patients with severe aortic stenosis. J Nucl Cardiol 24(4):1200\u20131213. https:\/\/doi.org\/10.1007\/s12350-016-0427-1","journal-title":"J Nucl Cardiol"},{"issue":"3","key":"2363_CR30","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.nuclcard.2008.02.013","volume":"15","author":"GS Thomas","year":"2008","unstructured":"Thomas GS, Tammelin BR, Schiffman GL, Marquez R, Rice DL, Milikien D et al (2008) Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: a randomized, double-blind, placebo-controlled trial (RegCOPD trial). J Nucl Cardiol 15(3):319\u201328. https:\/\/doi.org\/10.1016\/j.nuclcard.2008.02.013","journal-title":"J Nucl Cardiol"},{"issue":"3","key":"2363_CR31","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.nuclcard.2008.02.009","volume":"15","author":"BR Leaker","year":"2008","unstructured":"Leaker BR, O\u2019Connor B, Hansel TT, Barnes PJ, Meng L, Mathur VS et al (2008) Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial. J Nucl Cardiol 15(3):329\u201336. https:\/\/doi.org\/10.1016\/j.nuclcard.2008.02.009","journal-title":"J Nucl Cardiol"},{"issue":"4","key":"2363_CR32","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s12350-012-9547-4","volume":"19","author":"BM Prenner","year":"2012","unstructured":"Prenner BM, Bukofzer S, Behm S, Feaheny K, McNutt BE (2012) A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease. J Nucl Cardiol 19(4):681\u2013692. https:\/\/doi.org\/10.1007\/s12350-012-9547-4","journal-title":"J Nucl Cardiol"},{"issue":"3","key":"2363_CR33","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s12350-019-01851-4","volume":"27","author":"SRI Schiopu","year":"2020","unstructured":"Schiopu SRI, Zacherl M, Todica A, Bartenstein P, Milger K, Leuschner G et al (2020) Feasibility and accuracy of SPECT myocardial perfusion imaging in end-stage lung disease. J Nucl Cardiol 27(3):903\u2013911. https:\/\/doi.org\/10.1007\/s12350-019-01851-4","journal-title":"J Nucl Cardiol"},{"issue":"14","key":"2363_CR34","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/j.jacc.2019.07.074","volume":"74","author":"RY Kwong","year":"2019","unstructured":"Kwong RY, Ge Y, Steel K, Bingham S, Abdullah S, Fujikura K et al (2019) Cardiac magnetic resonance stress perfusion imaging for evaluation of patients with chest pain. J Am Coll Cardiol 74(14):1741\u20131755. https:\/\/doi.org\/10.1016\/j.jacc.2019.07.074","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2363_CR35","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1007\/s12350-017-1081-y","volume":"26","author":"E Andrikopoulou","year":"2019","unstructured":"Andrikopoulou E, Morgan CJ, Brice L, Bajaj NS, Doppalapudi H, Iskandrian AE et al (2019) Incidence of atrioventricular block with vasodilator stress SPECT: a meta-analysis. J Nucl Cardiol 26(2):616\u2013628. https:\/\/doi.org\/10.1007\/s12350-017-1081-y","journal-title":"J Nucl Cardiol"},{"issue":"5","key":"2363_CR36","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1007\/s12350-014-0036-9","volume":"22","author":"MO Rangel","year":"2015","unstructured":"Rangel MO, Morales Demori R, Voll ST, Wassouf M, Dick R, Doukky R (2015) Severe chronic kidney disease as a predictor of benefit from aminophylline administration in patients undergoing regadenoson stress myocardial perfusion imaging: a substudy of the ASSUAGE and ASSUAGE-CKD trials. J Nucl Cardiol 22(5):1008\u20131018. https:\/\/doi.org\/10.1007\/s12350-014-0036-9","journal-title":"J Nucl Cardiol"},{"issue":"1","key":"2363_CR37","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s12350-017-1038-1","volume":"25","author":"A Gupta","year":"2018","unstructured":"Gupta A, Bajaj NS (2018) Regadenoson use for stress myocardial perfusion imaging in advance chronic kidney disease and dialysis: safe, effective, and efficient. J Nucl Cardiol. 25(1):150\u2013152. https:\/\/doi.org\/10.1007\/s12350-017-1038-1","journal-title":"J Nucl Cardiol."},{"issue":"1","key":"2363_CR38","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s12350-011-9474-9","volume":"19","author":"GJ Zoghbi","year":"2012","unstructured":"Zoghbi GJ, Iskandrian AE (2012) Selective adenosine agonists and myocardial perfusion imaging. J Nucl Cardiol 19(1):126\u2013141","journal-title":"J Nucl Cardiol"},{"issue":"2","key":"2363_CR39","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s12350-012-9654-2","volume":"20","author":"R Doukky","year":"2013","unstructured":"Doukky R, Rangel MO, Wassouf M, Dick R, Alqaid A, Morales DR (2013) The safety and tolerability of regadenoson in patients with end-stage renal disease: the first prospective evaluation. J Nucl Cardiol 20(2):205\u2013213","journal-title":"J Nucl Cardiol"},{"issue":"2","key":"2363_CR40","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s12350-011-9508-3","volume":"19","author":"K Ananthasubramaniam","year":"2012","unstructured":"Ananthasubramaniam K, Weiss R, McNutt B, Klauke B, Feaheny K, Bukofzer S (2012) A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease. J Nucl Cardiol 19(2):319\u2013329","journal-title":"J Nucl Cardiol"},{"key":"2363_CR41","unstructured":"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/gadolinium_contrast_agents_31\/European_Commission_final_decision\/WC500240571.Pdf"},{"key":"2363_CR42","unstructured":"ACR manual on contrast media version 10.3. ACR Comitee on drugs and contrast media. American College of Radiology, 2018"},{"issue":"7","key":"2363_CR43","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1007\/s00330-019-06171-2","volume":"29","author":"J Uhlig","year":"2019","unstructured":"Uhlig J, L\u00fccke C, Vliegenthart R, Loewe C, Grothoff M, Schuster A et al (2019) Acute adverse events in cardiac MR imaging with gadolinium-based contrast agents: results from the European Society of Cardiovascular Radiology (ESCR) MRCT Registry in 72,839 patients. Eur Radiol 29(7):3686\u20133695. https:\/\/doi.org\/10.1007\/s00330-019-06171-2","journal-title":"Eur Radiol"},{"issue":"12","key":"2363_CR44","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1007\/s00259-019-04463-9","volume":"46","author":"A Katsikis","year":"2019","unstructured":"Katsikis A, Kyrozi E, Manira V, Theodorakos A, Malamitsi J, Tsapaki V et al (2019) Gender-related differences in side-effects and hemodynamic response to regadenoson in patients undergoing SPECT myocardial perfusion imaging. Eur J Nucl Med Mol Imaging 46(12):2590\u20132600. https:\/\/doi.org\/10.1007\/s00259-019-04463-9","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"15","key":"2363_CR45","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/1532-429X-15-108","volume":"21","author":"BH Freed","year":"2013","unstructured":"Freed BH, Narang A, Bhave NM, Czobor P, Mor-Avi V, Zaran ER et al (2013) Prognostic value of normal regadenoson stress perfusion cardiovascular magnetic resonance. J Cardiovasc Magn Reson 21(15):108. https:\/\/doi.org\/10.1186\/1532-429X-15-108","journal-title":"J Cardiovasc Magn Reson"},{"issue":"2","key":"2363_CR46","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s12350-014-9981-6","volume":"22","author":"JJ Mahmarian","year":"2015","unstructured":"Mahmarian JJ, Peterson LE, Xu J, Cerqueira MD, Iskandrian AE, Bateman TM et al (2015) Regadenoson provides perfusion results comparable to adenosine in heterogeneous patient populations: a quantitative analysis from the ADVANCE MPI trials. J Nucl Cardiol 22(2):248\u2013261. https:\/\/doi.org\/10.1007\/s12350-014-9981-6","journal-title":"J Nucl Cardiol"},{"issue":"7","key":"2363_CR47","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/s10554-011-0003-3","volume":"28","author":"Z Husain","year":"2012","unstructured":"Husain Z, Palani G, Cabrera R, Karthikeyan AS, Dhanalakota S, Pathmanathan S et al (2012) Hemodynamic response, arrhythmic risk, and overall safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic obstructive pulmonary disease and bronchial asthma patients. Int J Cardiovasc Imaging 28(7):1841\u20131849. https:\/\/doi.org\/10.1007\/s10554-011-0003-3","journal-title":"Int J Cardiovasc Imaging"}],"container-title":["The International Journal of Cardiovascular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10554-021-02363-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10554-021-02363-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10554-021-02363-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,6]],"date-time":"2022-02-06T18:02:36Z","timestamp":1644170556000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10554-021-02363-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,31]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["2363"],"URL":"https:\/\/doi.org\/10.1007\/s10554-021-02363-4","relation":{},"ISSN":["1569-5794","1573-0743"],"issn-type":[{"value":"1569-5794","type":"print"},{"value":"1573-0743","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,31]]},"assertion":[{"value":"3 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The registry was approved by the institutional review board, and written informed consent was obtained from all the subjects included.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval consent to participate"}}]}}